Skip to main content

Articles

Page 4 of 104

  1. Cell adhesion is indispensable for appropriate tissue architecture and function in multicellular organisms. Besides maintaining tissue integrity, cell adhesion molecules, including tight-junction proteins clau...

    Authors: Yuko Murakami-Nishimagi, Kotaro Sugimoto, Makoto Kobayashi, Kazunoshin Tachibana, Manabu Kojima, Maiko Okano, Yuko Hashimoto, Shigehira Saji, Tohru Ohtake and Hideki Chiba
    Citation: Breast Cancer Research 2023 25:41
  2. Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country...

    Authors: Xi Zhang, Aparna Gunda, Elma Meershoek-Klein Kranenbarg, Gerrit-Jan Liefers, Badada Ananthamurthy Savitha, Payal Shrivastava, Chandra Prakash Vijay Kumar Serkad, Taranjot Kaur, Mallikarjuna Siraganahalli Eshwaraiah, Rob A. E. M. Tollenaar, Cornelis J. H. van de Velde, Caroline M. J. Seynaeve, Manjiri Bakre and Peter J. K. Kuppen
    Citation: Breast Cancer Research 2023 25:40
  3. Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with c...

    Authors: Judith M. Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Elizabeth Mallon, Raghavan Vidya, Anthony Skene, Andrew Dodson, Margaret Hills, Simone Detre, Lila Zabaglo, Jane Banerji, Lucy Kilburn, James P. Morden, John F. R. Robertson…
    Citation: Breast Cancer Research 2023 25:39
  4. Radiotherapy is widely applied in breast cancer treatment, while radiotherapy resistance is inevitable. TGF-β1 has been considered to be an endogenous factor for the development of radiotherapy resistance. As ...

    Authors: Fayun Zhang, Zifeng Zheng, Luoyang Wang, Wenfeng Zeng, Wenjing Wei, Chunling Zhang, Ziran Zhao and Wei Liang
    Citation: Breast Cancer Research 2023 25:38
  5. Metastasis is a multistep process that leads to the formation of clinically detectable tumor foci at distant organs and frequently to patient demise. Only a subpopulation of breast cancer cells within the prim...

    Authors: Camille L. Duran, George S. Karagiannis, Xiaoming Chen, Ved P. Sharma, David Entenberg, John S. Condeelis and Maja H. Oktay
    Citation: Breast Cancer Research 2023 25:37
  6. When ipsilateral multifocal primary breast cancer (IMBC) is detected, standard routine is to evaluate the largest tumor with immunohistochemistry (IHC). As all foci are not routinely characterized, many patien...

    Authors: Slavica Janeva, Ellen Krabbe, Toshima Z. Parris, Salmir Nasic, Marie Sundquist, Per Karlsson, Riccardo A. Audisio, Roger Olofsson Bagge and Anikó Kovács
    Citation: Breast Cancer Research 2023 25:36
  7. High mammographic breast density (MBD) is an established risk factor for breast cancer (BC). Body fatness conveys an increased BC risk in postmenopause but is associated with less dense breasts. Here, we studi...

    Authors: Giovanna Masala, Benedetta Bendinelli, Saverio Caini, Giacomo Duroni, Ilaria Ermini, Elisa Pastore, Miriam Fontana, Luigi Facchini, Andrea Querci, Maria Antonietta Gilio, Vincenzo Mazzalupo, Melania Assedi, Daniela Ambrogetti and Domenico Palli
    Citation: Breast Cancer Research 2023 25:35
  8. HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.

    Authors: Xi′e Hu, Ping Yang, Songhao Chen, Gang Wei, Lijuan Yuan, Zhenyu Yang, Li Gong, Li He, Lin Yang, Shujia Peng, Yanming Dong, Xianli He and Guoqiang Bao
    Citation: Breast Cancer Research 2023 25:34
  9. We investigated the associations of alcohol with percentage of epithelium, stroma, fibroglandular tissue (epithelium + stroma), and fat in benign breast biopsy samples.

    Authors: Lusine Yaghjyan, Yujing J. Heng, Gabrielle M. Baker, Bernard A. Rosner and Rulla M. Tamimi
    Citation: Breast Cancer Research 2023 25:33
  10. Disseminated tumor cells (DTCs) in the bone marrow are observed in about 40% at primary diagnosis of breast cancer and predict poor survival. While anti-resorptive therapy with bisphosphonates was shown to era...

    Authors: Pauline Wimberger, Jens-Uwe Blohmer, Petra Krabisch, Theresa Link, Marianne Just, Bruno Valentin Sinn, Eike Simon, Christine Solbach, Tanja Fehm, Carsten Denkert, Cristin Kühn, Kerstin Rhiem, Hans Tesch, Sherko Kümmel, Andrea Petzold, Oliver Stötzer…
    Citation: Breast Cancer Research 2023 25:32
  11. Metastatic breast cancer is responsible for the death of the majority of breast cancer patients. In fact, metastatic BC is the 2nd leading cause of cancer-related deaths in women in the USA and worldwide. Trip...

    Authors: Wei Wang, Priyanka S. Rana, Vesna Markovic and Khalid Sossey-Alaoui
    Citation: Breast Cancer Research 2023 25:31
  12. Breast cancer (BC) treatments and related symptoms may affect return to work (RTW). The objective of this study was to investigate the impact of BC care pathways (timing and sequence of treatments) and related...

    Authors: Anne-Lise Rolland, Bertrand Porro, Sofiane Kab, Céline Ribet, Yves Roquelaure and Mélanie Bertin
    Citation: Breast Cancer Research 2023 25:30
  13. Metastatic breast cancer (MBC) is a challenging disease, and despite new therapies, prognosis is still poor for a majority of patients. There is a clinical need for improved prognostication where immuno-oncolo...

    Authors: Frida Björk Gunnarsdottir, Pär-Ola Bendahl, Alexandra Johansson, Rui Benfeitas, Lisa Rydén, Caroline Bergenfelz and Anna-Maria Larsson
    Citation: Breast Cancer Research 2023 25:29
  14. Authors: Toru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi and Naoki Niikura
    Citation: Breast Cancer Research 2023 25:28

    The original article was published in Breast Cancer Research 2023 25:13

  15. Inflammatory alterations of the extracellular matrix shape the tumor microenvironment and promote all stages of carcinogenesis. This study aims to determine the impact of cellular fibronectin on inflammatory f...

    Authors: Gurcan Tunali, Hamdullah Yanik, Suleyman Can Ozturk, Secil Demirkol-Canli, Georgios Efthymiou, Kerim Bora Yilmaz, Ellen Van Obberghen-Schilling and Gunes Esendagli
    Citation: Breast Cancer Research 2023 25:27
  16. RET, a single-pass receptor tyrosine kinase encoded on human chromosome 10, is well known to the field of developmental biology for its role in the ontogenesis of the central and enteric nervous systems and th...

    Authors: Geoffrey Pecar, Simeng Liu, Jagmohan Hooda, Jennifer M. Atkinson, Steffi Oesterreich and Adrian V. Lee
    Citation: Breast Cancer Research 2023 25:26
  17. Triple-negative breast cancer (TNBC) is highly aggressive with an increased metastatic incidence compared to other breast cancer subtypes. However, due to the absence of clinically reliable biomarkers and targ...

    Authors: Sanjib Chaudhary, Muthamil Iniyan Appadurai, Shailendra Kumar Maurya, Palanisamy Nallasamy, Saravanakumar Marimuthu, Ashu Shah, Pranita Atri, Chirravuri Venkata Ramakanth, Subodh M. Lele, Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Mohd W. Nasser, Apar Kishor Ganti, Surinder K. Batra and Imayavaramban Lakshmanan
    Citation: Breast Cancer Research 2023 25:25
  18. Higher circulating prolactin has been associated with increased breast cancer risk. Prolactin binding to the prolactin receptor (PRLR) can activate the transcription factor STAT5, thus, we examined the associa...

    Authors: Cassandra A. Hathaway, Megan S. Rice, Laura C. Collins, Dilys Chen, David A. Frank, Sarah Walker, Charles V. Clevenger, Rulla M. Tamimi, Shelley S. Tworoger and Susan E. Hankinson
    Citation: Breast Cancer Research 2023 25:24
  19. Stratifying breast cancer into specific molecular or histologic subtypes aids in therapeutic decision-making and predicting outcomes; however, these subtypes may not be as distinct as previously thought. Patie...

    Authors: Gadisti Aisha Mohamed, Sundis Mahmood, Nevena B. Ognjenovic, Min Kyung Lee, Owen M. Wilkins, Brock C. Christensen, Kristen E. Muller and Diwakar R. Pattabiraman
    Citation: Breast Cancer Research 2023 25:23
  20. Breast cancer is the major cause of death in females globally. Chemokine-like factor like MARVEL transmembrane domain containing 7 (CMTM7) is reported as a tumor suppressor and is involved in epidermal growth ...

    Authors: Zhao-Hui Chen, Yao Tian, Guang-Lei Zhou, Hao-Ran Yue, Xue-Jie Zhou, Hai-Yan Ma, Jie Ge, Xin Wang, Xu-Chen Cao and Yue Yu
    Citation: Breast Cancer Research 2023 25:22
  21. The intratumor heterogeneity (ITH) of cancer cells plays an important role in breast cancer resistance and recurrence. To develop better therapeutic strategies, it is necessary to understand the molecular mech...

    Authors: Sumito Saeki, Kohei Kumegawa, Yoko Takahashi, Liying  Yang, Tomo Osako, Mahmut Yasen, Kazutaka Otsuji, Kenichi Miyata, Kaoru Yamakawa, Jun Suzuka, Yuri Sakimoto, Yukinori Ozaki, Toshimi Takano, Takeshi Sano, Tetsuo Noda, Shinji Ohno…
    Citation: Breast Cancer Research 2023 25:21
  22. Mammography screening has been proven to detect breast cancer at an early stage and reduce mortality; however, it has low accuracy in young women or women with dense breasts. Blood-based diagnostic tools may o...

    Authors: Eun-Shin Lee, Yumi Kim, Hee-Chul Shin, Ki-Tae Hwang, Junwon Min, Min Kyoon Kim, SooKyung Ahn, So-Youn Jung, Hyukjai Shin, MinSung Chung, Tae-Kyung Yoo, Seungpil Jung, Sang Uk Woo, Ju-Yeon Kim, Dong-Young Noh and Hyeong-Gon Moon
    Citation: Breast Cancer Research 2023 25:20
  23. Chemotherapy is an important strategy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+HER2−) breast cancer (BC), but this subtype has a low response rate to...

    Authors: Dengjie Ouyang, Tao Hong, Mengdie Fu, Yitong Li, Liyun Zeng, Qitong Chen, Hongye He, Ying Wen, Yan Cheng, Meirong Zhou, Qiongyan Zou and Wenjun Yi
    Citation: Breast Cancer Research 2023 25:19
  24. Second primary cancer incidence is rising among breast cancer survivors. We examined the risks of non-breast second primaries, in combination and at specific cancer sites, through a systematic review and meta-...

    Authors: Isaac Allen, Hend Hassan, Eleni Sofianopoulou, Diana Eccles, Clare Turnbull, Marc Tischkowitz, Paul Pharoah and Antonis C. Antoniou
    Citation: Breast Cancer Research 2023 25:18
  25. Authors: Mikhail V. Pavlov, Anna P. Bavrina, Vladimir I. Plekhanov, German Yu. Golubyatnikov, Anna G. Orlova, Pavel V. Subochev, Diana A. Davydova, Ilya V. Turchin and Anna V. Maslennikova
    Citation: Breast Cancer Research 2023 25:16

    The original article was published in Breast Cancer Research 2023 25:12

  26. Authors: Oluwatosin A. Ayeni, Maureen Jofe, Witness Mapanga, Wenlong Carl Chen, Daniel S. O’Neil, Boitumelo Phakathi, Sarah Nietz, Ines Buccimazza, Sharon Čačala, Laura W. Stopforth, Judith S. Jacobson, Katherine D. Crew, Alfred I. Neugut, Duvern Ramiah, Paul Ruf, Herbert Cubasch…
    Citation: Breast Cancer Research 2023 25:14

    The original article was published in Breast Cancer Research 2023 25:7

  27. Elucidating the unique immunoregulatory mechanisms in breast cancer microenvironment may help develop new therapeutic strategies. Some studies have suggested that hormone receptors also have immune regulatory ...

    Authors: Toru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi and Naoki Niikura
    Citation: Breast Cancer Research 2023 25:13

    The Correction to this article has been published in Breast Cancer Research 2023 25:28

  28. Breast cancer neoadjuvant chemotherapy (NACT) allows for assessing tumor sensitivity to systemic treatment, planning adjuvant treatment and follow-up. However, a sufficiently large number of patients fail to a...

    Authors: Mikhail V. Pavlov, Anna P. Bavrina, Vladimir I. Plekhanov, German Yu. Golubyatnikov, Anna G. Orlova, Pavel V. Subochev, Diana A. Davydova, Ilya V. Turchin and Anna V. Maslennikova
    Citation: Breast Cancer Research 2023 25:12

    The Correction to this article has been published in Breast Cancer Research 2023 25:16

  29. Metaplastic breast carcinoma (MpBC) typically consists of carcinoma of no special type (NST) with various metaplastic components. Although previous transcriptomic and proteomic studies have reported subtype-re...

    Authors: Huang-Chun Lien, Chia-Lang Hsu, Yen-Shen Lu, Tom Wei-Wu Chen, I.-Chun Chen, Yu-Chia Li, Chiun-Sheng Huang, Ann-Lii Cheng and Ching-Hung Lin
    Citation: Breast Cancer Research 2023 25:11
  30. Necroptosis is a form of regulated necrosis and is executed by MLKL when MLKL is engaged in triggering the rupture of cell plasma membrane. MLKL activation also leads to the protease, ADAMs-mediated ectodomain...

    Authors: Zhaoshan Liu, Swati Choksi, Hyung-Joon Kwon, Delong Jiao, Chengyu Liu and Zheng-gang Liu
    Citation: Breast Cancer Research 2023 25:10
  31. Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to scree...

    Authors: Yu Wang, Fanghua Liu, Lulu Sun, Yiming Jia, Pinni Yang, Daoxia Guo, Mengyao Shi, Aili Wang, Guo-Chong Chen, Yonghong Zhang and Zhengbao Zhu
    Citation: Breast Cancer Research 2023 25:9
  32. Guidelines recommend shared decision making (SDM) for mammography screening for women ≥ 75 and not screening women with < 10-year life expectancy. High-quality SDM requires consideration of women’s breast canc...

    Authors: Mara A. Schonberg, Emily A. Wolfson, A. Heather Eliassen, Kimberly A. Bertrand, Yurii B. Shvetsov, Bernard A. Rosner, Julie R. Palmer and Long H. Ngo
    Citation: Breast Cancer Research 2023 25:8
  33. Breast cancer survival in South Africa is low, but when diagnosed with breast cancer, many women in South Africa also have other chronic conditions. We investigated the impact of multimorbidity (≥ 2 other chro...

    Authors: Oluwatosin A. Ayeni, Maureen Joffe, Witness Mapanga, Wenlong Carl Chen, Daniel S. O’Neil, Boitumelo Phakathi, Sarah Nietz, Ines Buccimazza, Sharon Čačala, Laura W. Stopforth, Judith S. Jacobson, Katherine D. Crew, Alfred I. Neugut, Duvern Ramiah, Paul Ruff, Herbert Cubasch…
    Citation: Breast Cancer Research 2023 25:7

    The Correction to this article has been published in Breast Cancer Research 2023 25:14

  34. A challenge in human mammary epithelial cell (HMEC) culture is sustaining the representation of competing luminal, myoepithelial, and progenitor lineages over time. As cells replicate in culture, myoepithelial...

    Authors: Michael E. Todhunter, Masaru Miyano, Eric G. Carlson, Stefan Hinz and Mark A. LaBarge
    Citation: Breast Cancer Research 2023 25:6
  35. Breast cancer incidence rates have not declined despite an improvement in risk prediction and the identification of modifiable risk factors, suggesting the need to identify novel risk factors and etiological p...

    Authors: Victoria L. Stevens, Brian D. Carter, Eric J. Jacobs, Marjorie L. McCullough, Lauren R. Teras and Ying Wang
    Citation: Breast Cancer Research 2023 25:5

    The Correction to this article has been published in Breast Cancer Research 2023 25:15

  36. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ca...

    Authors: Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joon Jeong and Joohyuk Sohn
    Citation: Breast Cancer Research 2023 25:4
  37. The chemotherapy of triple-negative breast cancer based on doxorubicin (DOX) regimens suffers from great challenges on toxicity and autophagy raised off-target. In this study, a conjugate methotrexate-polyethy...

    Authors: Zhiwen Cao, Rui Liu, Yang Li, Xinyi Luo, Zhenglai Hua, Xiangpeng Wang, Zeyu Xue, Zhengjia Zhang, Cheng Lu, Aiping Lu and Yuanyan Liu
    Citation: Breast Cancer Research 2023 25:3
  38. KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III bre...

    Authors: Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet and Sara A. Hurvitz
    Citation: Breast Cancer Research 2023 25:2
  39. Breast cancer mortality is principally due to recurrent disease that becomes resistant to therapy. We recently identified copy number (CN) gain of the putative membrane progesterone receptor PAQR8 as one of four ...

    Authors: Saisai Chen, Matt R. Paul, Christopher J. Sterner, George K. Belka, Dezhen Wang, Peining Xu, Amulya Sreekumar, Tien-chi Pan, Dhruv K. Pant, Igor Makhlin, Angela DeMichele, Clementina Mesaros and Lewis A. Chodosh
    Citation: Breast Cancer Research 2023 25:1
  40. This systematic review aimed to assess the methods used to classify mammographic breast parenchymal features in relation to the prediction of future breast cancer. The databases including Medline (Ovid) 1946-,...

    Authors: Akila Anandarajah, Yongzhen Chen, Graham A. Colditz, Angela Hardi, Carolyn Stoll and Shu Jiang
    Citation: Breast Cancer Research 2022 24:101
  41. After many years of neglect in the field of alternative splicing, the importance of intron retention (IR) in cancer has come into focus following landmark discoveries of aberrant IR patterns in cancer. Many so...

    Authors: Jaynish S. Shah, Michael J. G. Milevskiy, Veronika Petrova, Amy Y. M. Au, Justin J. L. Wong, Jane E. Visvader, Ulf Schmitz and John E. J. Rasko
    Citation: Breast Cancer Research 2022 24:100
  42. Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor ty...

    Authors: Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Liping Ye, Chengming Zhu, Liang Deng, Bo Wang, Yihang Pan and Peng Li
    Citation: Breast Cancer Research 2022 24:99
  43. Breast cancer is the most diagnosed cancer among women. Approximately 15–20% of all breast cancers are highly invasive triple-negative breast cancer (TNBC) and lack estrogen, progesterone, and ERBB2 receptors....

    Authors: Natalie S. Joe, Inês Godet, Nubaira Milki, Noor U. I. Ain, Harsh H. Oza, Gregory J. Riggins and Daniele M. Gilkes
    Citation: Breast Cancer Research 2022 24:98
  44. A preoperative-progesterone intervention increases disease-free survival in patients with breast cancer, with an unknown underlying mechanism. We elucidated the role of non-coding RNAs in response to progester...

    Authors: Neelima Yadav, Roma Sunder, Sanket Desai, Bhasker Dharavath, Pratik Chandrani, Mukul Godbole and Amit Dutt
    Citation: Breast Cancer Research 2022 24:97
  45. Dense breast notification (DBN) legislation aims to increase a woman’s awareness of her personal breast density and the implications of having dense breasts for breast cancer detection and risk. This informati...

    Authors: Erica J. Lee Argov, Carmen B. Rodriguez, Mariangela Agovino, Ying Wei, Rachel C. Shelton, Rita Kukafka, Karen M. Schmitt, Elise Desperito, Mary Beth Terry and Parisa Tehranifar
    Citation: Breast Cancer Research 2022 24:95
  46. During cancer development, the normal tissue microenvironment is shaped by tumorigenic events. Inflammatory mediators and immune cells play a key role during this process. However, which molecular features mos...

    Authors: Philémon Sirven, Lilith Faucheux, Maximilien Grandclaudon, Paula Michea, Anne Vincent-Salomon, Fatima Mechta-Grigoriou, Alix Scholer-Dahirel, Maude Guillot-Delost and Vassili Soumelis
    Citation: Breast Cancer Research 2022 24:94
  47. Breast cancer (BC) grading plays a critical role in patient management despite the considerable inter- and intra-observer variability, highlighting the need for decision support tools to improve reproducibilit...

    Authors: Gerardo Fernandez, Marcel Prastawa, Abishek Sainath Madduri, Richard Scott, Bahram Marami, Nina Shpalensky, Krystal Cascetta, Mary Sawyer, Monica Chan, Giovanni Koll, Alexander Shtabsky, Aaron Feliz, Thomas Hansen, Brandon Veremis, Carlos Cordon-Cardo, Jack Zeineh…
    Citation: Breast Cancer Research 2022 24:93

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2022 Speed
    27 days submission to first editorial decision for all manuscripts (Median)
    166 days submission to accept (Median)

    2022 Usage 
    2,233,470 downloads
    8,627 Altmetric mentions